ReviewFrontiers in pharmacology2025
Progress in the study of the effects of selective serotonin reuptake inhibitors (SSRIs) on the reproductive system.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats.Journal of molecular histology · 2026Article
- Article
- Fluoxetine Disrupts Ovarian Serotonin Signaling and Oocyte Competence in Mice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations.Healthcare (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the increasing number of infertility cases has led to a greater research focus on the reproductive toxicity of drugs due to the fact that some classes of pharmacotherapeutic agents have been found to exert deleterious effects on the reproductive system. Depressive disorders are a class of common mental illnesses that seriously damage human health. The variety of antidepressant drugs is large and the incidence of adverse effects is high. Selective serotonin reuptake inhibitors (SSRIs), as the first-line drugs for the treatment of depression, have remarkable efficacy, but at the same time there is a widespread abuse of them, which not only creates an unfavorable impact on one's own reproductive system, but also may cause reproductive damage to other non-target populations through pathways, such as the water column. The review provides an introduction to the reproductive toxicity of SSRIs from the aspects of male and female germ cell genesis, embryonic development, reproductive system maturation, and environmental contamination, and it briefly describes the potential mechanisms underlying SSRI-induced reproductive toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.